Enteral Nutritional Therapy

Enteral nutritional therapy (ENT) refers to the provision of nutrients directly into the gastrointestinal (GI) tract through a tube when oral intake is insufficient, unsafe, or impossible. It is a cornerstone of modern clinical nutrition, supporting recovery, preserving gut integrity, and reducing complications associated with malnutrition.

Why Enteral Nutrition?

Approximately 3050% of hospitalized patients develop some degree of malnutrition, which is linked to longer stays, higher infection rates, and increased mortality. When the digestive system is functional, delivering calories and protein through the gut is preferable to parenteral (intravenous) feeding because:

• Maintains gut mucosal integrity and prevents bacterial translocation.
• Promotes normal hormonal responses (e.g., incretins).
• Is more physiologic and generally less expensive.
• Reduces risk of catheterrelated bloodstream infections.

Indications

Enteral nutrition is indicated whenever a patient cannot meet 60% of their estimated energy needs orally for more than 57 days, provided the GI tract is patent. Common scenarios include:

1. Neurological impairment (stroke, traumatic brain injury, spinal cord injury).
2. Head and neck cancers limiting oral intake.
3. Severe dysphagia or aspiration risk.
4. Critical illness (severe sepsis, burns, major trauma).
5. Pancreatitis or short bowel syndrome where oral feeding is contraindicated.

Routes of Delivery

Nasogastric (NG) Tube

Inserted through the nose to the stomach, NG tubes are quick to place and suitable for shortterm feeding (<46 weeks). They are ideal for patients with a functional stomach and no high risk of aspiration.

Nasoduodenal/Nasojejunal (NJ) Tube

These tubes pass beyond the pylorus into the duodenum or jejunum. They are used when gastric feeding is poorly tolerated, when there is a high aspiration risk, or when gastric residual volumes remain elevated despite prokinetic agents.

Gastrostomy (PEG/PG)

Percutaneous endoscopic gastrostomy (PEG) is the preferred method for longterm enteral access (>4 weeks). It provides a stable, lowmaintenance route and can be placed at the bedside in many cases.

Jejunostomy (Jtube)

Enteral access directly into the jejunum is chosen when gastric feeding is contraindicated (e.g., severe gastroparesis, high aspiration risk) and longterm therapy is required.

Formulas and Their Selection

The choice of formula depends on the patients metabolic state, disease process, and tolerance. Common categories include:

• Standard polymeric formulas contain intact proteins, carbohydrates, and fats; suitable for most patients.
• Elemental / semielemental formulas hydrolyzed proteins and mediumchain triglycerides; used for malabsorption, severe pancreatitis, or short bowel.
• Specialized formulas high protein, immunemodulating (e.g., arginine, glutamine, omega3), renal, or diabetic formulas.

Key parameters to consider when prescribing:

Initiation and Advancement

A typical protocol:

1. Day1 assessment: confirm tube placement (pH testing, Xray if needed), determine caloric target.
2. Day12 start low: 1020% of goal calories over 1224h, usually via continuous pump.
3. Day35 increment: increase by 1020% every 1224h as tolerated.
4. Day57 reach goal: achieve full prescribed volume unless intolerance persists.

Monitoring includes gastric residual volumes (GRV), abdominal distension, bowel sounds, and metabolic labs (glucose, electrolytes, liver enzymes).

Complications and Management

Mechanical

• Tube displacement or occlusion verify placement, flush regularly with water.
• Nasopharyngeal discomfort reposition, consider a smallerdiameter tube.

Gastrointestinal

• Diarrhea assess for infection, medication effect, or osmolarity; consider fibercontaining or peptidebased formulas.
• Constipation increase fiber, add stimulant laxatives, ensure adequate hydration.
• Reflux/aspiration elevate head of bed 3045, use postpyloric feeding, consider prokinetics.

Metabolic

• Hyperglycemia use diabetesspecific formulas or insulin sliding scale.
• Refeeding syndrome start low and monitor electrolytes (phosphate, potassium, magnesium).

Monitoring & Evaluation

Effective ENT requires regular reassessment:

• Clinical weight, midarm circumference, wound healing, functional status.
• Laboratory prealbumin, CRP, electrolytes, liver function every 37 days.
• Feeding tolerance GRV <250mL, absence of vomiting, normal bowel pattern.

A multidisciplinary team (physician, dietitian, nurse, pharmacist, speechlanguage pathologist) optimizes outcomes.

Transitioning Off Enteral Feeding

When oral intake becomes adequate, a stepdown plan should be instituted:

1. Introduce oral diet while continuing a reduced enteral volume.
2. Gradually taper tube feeds over 35 days, monitoring caloric intake.
3. Remove tube once oral intake consistently meets 75% of needs.

Current Evidence & Guidelines

Major societiesincluding the American Society for Parenteral and Enteral Nutrition (ASPEN) and the European Society for Clinical Nutrition and Metabolism (ESPEN)recommend early (<48h) enteral nutrition for critically ill patients with a functional GI tract. Recent metaanalyses show that early EN reduces infectious complications by ~30% and shortens ICU stay by 23 days.

Practical Tips for Clinicians

• Always verify tube position before each feeding session.
• Keep the head of the bed elevated to lower aspiration risk.
• Document formula type, rate, and any changes in the patient chart.
• Educate patients and families on tube care to prevent accidental dislodgement.
• Review medications that may affect GI motility (e.g., opioids) and adjust when possible.